We concluded that the antileukemic activity of lenalidomide in CLL operates is at least partly through modulation of the STAT3 pathway and inhibition of IL-10 production by CLL-B cells. This evidence concerns the gene STAT3 and B-cell chronic lymphocytic leukemia.